Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1987-7-24
|
| pubmed:abstractText |
Interferon alfa-2b (Intron A; Schering Plough) has been shown to be active in advanced previously treated multiple myeloma (MM). Recent in vitro evidence has suggested synergy between cytotoxic agents and interferon alfa-2b. This phase I-II protocol was initiated to study interferon alfa-2b in combination with melphalan and prednisone. Groups of five patients received interferon alfa-2b twice-weekly for two weeks at dose levels of 0.5, 1.0, 2.0, 5.0 and 10.0 X 10(6) IU/m2. During week 2, melphalan (9 mg/m2) and prednisone (40 mg/m2) were administered concurrently with interferon alfa-2b followed by a rest period during nadir myelosuppression, the cycles being repeated every 28 days. Thirty patients were entered of whom 21 were Stage III, 3 Stage II and 6 Stage I. Median nadir WBC/mm3 and platelets/mm3 at the various dose levels are given in the table. Serious adverse reactions while on study included myocardial infarction, renal failure and leukopenia-related sepsis. Early response information is available. Twenty-six patients are evaluable for response. Seven have had progressive disease and 19 (69%) a partial response, the median duration was 11+ months. Interferon alfa-2b does not appear to antagonize melphalan/prednisone effectiveness and may be additive or synergistic. Full evaluation of this combination will be undertaken in randomized controlled trials which are now underway.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0167-6997
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
5 Suppl
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
S41-6
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:3597002-Acute Kidney Injury,
pubmed-meshheading:3597002-Adult,
pubmed-meshheading:3597002-Aged,
pubmed-meshheading:3597002-Aged, 80 and over,
pubmed-meshheading:3597002-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3597002-Drug Evaluation,
pubmed-meshheading:3597002-Drug Synergism,
pubmed-meshheading:3597002-Female,
pubmed-meshheading:3597002-Humans,
pubmed-meshheading:3597002-Interferon Type I,
pubmed-meshheading:3597002-Leukopenia,
pubmed-meshheading:3597002-Male,
pubmed-meshheading:3597002-Melphalan,
pubmed-meshheading:3597002-Middle Aged,
pubmed-meshheading:3597002-Multiple Myeloma,
pubmed-meshheading:3597002-Myocardial Infarction,
pubmed-meshheading:3597002-Prednisone,
pubmed-meshheading:3597002-Sepsis
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
|
| pubmed:publicationType |
Journal Article
|